ABSTRACT
AIM: To study persistent postural perceptual dizziness (PPPD) in outpatients with benign paroxysmal positional vertigo (BPPV) and patients with presbiataxia (PAt). MATERIAL AND METHODS: Eighty-four patients with PPPD, including 14 with Meniere's disease (MD), 19 with BPPV, 17 with a history of ischemic stroke (IS) in the vertebrobasilar system and 34 with Pat, were examined. For the diagnosis of anxiety, the original 15-point questionnaire with the Likert Scale structure was used. Patients received anvifen (aminophenylbutyric acid hydrochloride) in dose of 250 mg 3 times a day for 6 weeks. Results and Ñonclusion. The most common trigger of PPPD was sleep deprivation. The highest level of anxiety was identified in the PAt group (19,5±2,89). There was a good effect of the drug: it reduced anxiety in all patients studied. The quality of sleep was improved as well. The authors recommend anvifen as the drug of choice in patients with PPPD during vestibular rehabilitation and cognitive-behavioral therapy.
Subject(s)
Anxiety , Benign Paroxysmal Positional Vertigo , Dizziness , Meniere Disease , Anxiety/etiology , Benign Paroxysmal Positional Vertigo/complications , Benign Paroxysmal Positional Vertigo/diagnosis , Humans , Meniere Disease/complications , Meniere Disease/diagnosis , Surveys and QuestionnairesABSTRACT
The first section of the review provides recent results regarding the mechanism of the action of a standardized extract of ginkgo biloba leaves EGb761 (tanakan), its effects on apoptosis, neuroplasticity, hemorheology, inhibition of the amyloid genesis and inflammatory response it cause, activation of proteasomes in conformational diseases. Current experimental and clinical results suggest that EGb761 (tanakan) is a high-effective cytoprotective agent in cognitive disorders of various genesis, cardiovascular diseases (in the process of rehabilitation and as a medicine capable to reduce the volume of brain damage in stroke). The effect of tanakan on anxiety and depression in patients with cognitive impairment should be considered as clinically significant.
Subject(s)
Cerebrovascular Disorders/drug therapy , Cognition Disorders/drug therapy , Cytoprotection , Neuroprotective Agents/therapeutic use , Plant Extracts/therapeutic use , Anxiety/drug therapy , Apoptosis/drug effects , Cerebrovascular Disorders/psychology , Cognition/drug effects , Cognition Disorders/psychology , Depression/drug therapy , Ginkgo biloba , Humans , Neuronal Plasticity/drug effects , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacologyABSTRACT
The second section of the review provides an update of the data on mechanisms of action of a standardized extract of Ginkgo biloba EGb761® (tanakan) and its efficacy in treatment of depression, pain, complications of diabetes, Parkinson disease, tinnitus and dizziness, reproductive dysfunction. Updated data enable to use EGb761® (tanakan) as a highly-effective cytoprotective agent in treatment of cardiovascular, degenerative and metabolic diseases of the nervous system, inner ear disturbances (tinnitus), dysfunction of reproductive system as well as in prevention and treatment of stress-induced disorders.
